Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program.
Sartor O, Vogelzang NJ, Sweeney C, Fernandez DC, Almeida F, Iagaru A, Brown A Jr, Smith MR, Agrawal M, Dicker AP, Garcia JA, Lutzky J, Wong YN, Petrenciuc O, Gratt J, Shore ND, Morris MJ; U.S. Expanded Access Program Investigators. Sartor O, et al. Among authors: garcia ja. Oncologist. 2018 Feb;23(2):193-202. doi: 10.1634/theoncologist.2017-0413. Epub 2017 Nov 28. Oncologist. 2018. PMID: 29183960 Free PMC article. Clinical Trial.
Oral enzastaurin in prostate cancer: a two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease.
Dreicer R, Garcia J, Hussain M, Rini B, Vogelzang N, Srinivas S, Somer B, Zhao YD, Kania M, Raghavan D. Dreicer R, et al. Invest New Drugs. 2011 Dec;29(6):1441-8. doi: 10.1007/s10637-010-9428-0. Epub 2010 Apr 6. Invest New Drugs. 2011. PMID: 20369375 Clinical Trial.
A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer.
Dreicer R, Garcia J, Rini B, Vogelzang N, Srinivas S, Somer B, Shi P, Kania M, Raghavan D. Dreicer R, et al. Invest New Drugs. 2013 Aug;31(4):1044-50. doi: 10.1007/s10637-013-9940-0. Epub 2013 Feb 24. Invest New Drugs. 2013. PMID: 23435622 Clinical Trial.
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Sweeney CJ, et al. Among authors: garcia ja. N Engl J Med. 2015 Aug 20;373(8):737-46. doi: 10.1056/NEJMoa1503747. Epub 2015 Aug 5. N Engl J Med. 2015. PMID: 26244877 Free PMC article. Clinical Trial.
Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial.
Rini BI, Dorff TB, Elson P, Rodriguez CS, Shepard D, Wood L, Humbert J, Pyle L, Wong YN, Finke JH, Rayman PA, Larkin JM, Garcia JA, Plimack ER. Rini BI, et al. Among authors: garcia ja. Lancet Oncol. 2016 Sep;17(9):1317-24. doi: 10.1016/S1470-2045(16)30196-6. Epub 2016 Aug 3. Lancet Oncol. 2016. PMID: 27498080 Free PMC article. Clinical Trial.
Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.
Harshman LC, Chen YH, Liu G, Carducci MA, Jarrard D, Dreicer R, Hahn N, Garcia JA, Hussain M, Shevrin D, Eisenberger M, Kohli M, Plimack ER, Cooney M, Vogelzang NJ, Picus J, Dipaola R, Sweeney CJ; ECOG-ACRIN 3805 Investigators. Harshman LC, et al. Among authors: garcia ja. J Clin Oncol. 2018 Feb 1;36(4):376-382. doi: 10.1200/JCO.2017.75.3921. Epub 2017 Dec 20. J Clin Oncol. 2018. PMID: 29261442 Free PMC article. Clinical Trial.
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.
Koshkin VS, Barata PC, Zhang T, George DJ, Atkins MB, Kelly WJ, Vogelzang NJ, Pal SK, Hsu J, Appleman LJ, Ornstein MC, Gilligan T, Grivas P, Garcia JA, Rini BI. Koshkin VS, et al. Among authors: garcia ja. J Immunother Cancer. 2018 Jan 29;6(1):9. doi: 10.1186/s40425-018-0319-9. J Immunother Cancer. 2018. PMID: 29378660 Free PMC article.
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.
Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ. Kyriakopoulos CE, et al. Among authors: garcia ja. J Clin Oncol. 2018 Apr 10;36(11):1080-1087. doi: 10.1200/JCO.2017.75.3657. Epub 2018 Jan 31. J Clin Oncol. 2018. PMID: 29384722 Free PMC article. Clinical Trial.
Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.
Gravis G, Boher JM, Chen YH, Liu G, Fizazi K, Carducci MA, Oudard S, Joly F, Jarrard DM, Soulie M, Eisenberger MJ, Habibian M, Dreicer R, Garcia JA, Hussain MHM, Kohli M, Vogelzang NJ, Picus J, DiPaola R, Sweeney C. Gravis G, et al. Among authors: garcia ja. Eur Urol. 2018 Jun;73(6):847-855. doi: 10.1016/j.eururo.2018.02.001. Epub 2018 Feb 21. Eur Urol. 2018. PMID: 29475737 Free PMC article.
1,138 results